Adherence and Early Predictors of Response: Tools for Individualizing Treatment in Schizophrenia

Premiere Date: Monday, October 6, 2008

To receive CME/CE credit, view the complete one-hour webcast activity anytime at
www.neuroscienceCME.com/CMW317

neuro·science CME™
www.neuroscienceCME.com

Bonus Offer: Live Interaction with Experts on Featured Articles!

October 6, 2008, 12:00–12:45 p.m. ET (Stephen R. Marder, MD/Alan I. Green, MD)
October 27, 2008, 12:00–12:45 p.m. ET (Philip D. Harvey, PhD/Alan I. Green, MD)
November 24, 2008, 12:00–12:45 p.m. ET (John M. Kane, MD/Alan I. Green, MD)

- On these dates/times, call in to ask the faculty a question at **800.895.1713**
- For each date, the first 15 minutes will be a replay of respective faculty's lecture from the complete webcast
- Faculty will answer email questions for two weeks after their respective Q&A date
- Be advised that participation in the bonus Q&A sessions does not constitute additional credit or Live ACPE credit

Questions?
Call 877.CME.PROS

This activity offers CE credit for:
- Physicians (CME)
- Case Managers (CCMC)
- Social Workers (NASW)
- Psychologists (CEP)
- Nurses (CNE)
- Pharmacists (CPE)

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.

FACULTY INFORMATION
Philip D. Harvey, PhD
Emory University School of Medicine
Atlanta, GA

Featured Article: Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. *Schizophr Bull* 2008;34:483-493.

John M. Kane, MD
The Zucker Hillside Hospital
Glen Oaks, NY
The Albert Einstein College of Medicine
Bronx, NY

Featured Article: Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. *J Clin Psychiatry* 2007;68:352-360.

Stephen R. Marder, MD
David Geffen School of Medicine at UCLA
Los Angeles, CA

Featured Article: Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet* 2008;371:1085-1097.

MODERATOR
Alan I. Green, MD
Dartmouth Medical School
Lebanon, NH

CREDIT INFORMATION
CME Credit (Physicians): CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

CNE Credit (Nurses): CME Outfitters, LLC, is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

It has been assigned code 6WASUP-PRV-0642. 1.0 contact hours will be awarded upon successful completion.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

CEP Credit (Psychologists): CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters maintains responsibility for this program and its content. (1.0 CE credits)

NASW Credit (Social Workers): This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.

CCMC Credit (Certified Case Managers): This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).

CPE Credit (Pharmacists): CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)

Universal Program Number: 376-000-08-019-H01-P

Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Resources tab–requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). CE credit expires on October 6, 2009.

STATEMENT OF NEED
Developing and following an effective maintenance treatment plan is vital to achieving remission and long-term functional recovery in patients with schizophrenia. Critical to selecting optimal pharmacotherapy in support of long-term recovery is appropriate weighing of the benefits, risks, and complexity of the treatment regimen. Each of these elements can impact adherence to pharmacotherapy, which in turn can impact outcome. Rates of medication nonadherence in patients with schizophrenia range from 40-55%.[1] Recent evidence suggests that disease- and patient-related characteristics can predict the extent of adherence and can be used to tailor behavioral interventions.[2] New data also indicate that early response to antipsychotic medications can predict longer-term outcome, and may allow physicians to abandon ineffective medications earlier in favor or more appropriate options.[3] In this journal club series, experts will review cutting edge data related to efficacy and safety of atypical antipsychotics, approaches to improving medication adherence, and strategies for identifying early non-responders, all of which will impact long-term functional outcome in patients with schizophrenia.

[1] Lacro JP, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *J Clin Psychiatry* 2002;63:892-909.
[2] Velligan DI, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. *Schizophr Bull* 2008;34:483-493.
[3] Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. *J Clin Psychiatry* 2007;68:352-360.

ACTIVITY GOAL
To provide mental healthcare practitioners with the most recent data and clinical implications related to optimizing maintenance therapy in schizophrenia.

LEARNING OBJECTIVES
At the end of this CE activity, participants should be able to:
- Discuss the implications of differential efficacy and tolerability of antipsychotics on medication adherence.
- Identify targeted behavioral approaches to improving treatment adherence in patients with schizophrenia.
- Describe early predictors of response to antipsychotic medication in patients with schizophrenia.

TARGET AUDIENCE
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals interested in methods for optimizing outcomes with maintenance antipsychotic therapy in patients with schizophrenia.

COMMERCIAL SUPPORT
CME Outfitters, LLC, gratefully acknowledges an educational grant from AstraZeneca Pharmaceuticals in support of this CE activity.

FAX completed form to 240.243.1033

❑ **YES! Register me for the Journal Club Webcast.** (Participation details will be sent to you via email.)
YES! Please also register me for the following bonus live interactive Q&A session(s).

| October 6, 2008 | ❑ online ❑ by phone | November 24, 2008 | ❑ online ❑ by phone |
| October 27, 2008 | ❑ online ❑ by phone | All three dates | ❑ online ❑ by phone |

Site Name:_____ # Participants:_____

Individual Name:_____ Degree:_____

Address:_____

City/State/ZIP:_____

Practice Setting: ❑ Community Mental Health ❑ State Mental Health ❑ Primary Care ❑ Private Practice ❑ Other:_____ Phone:_____

Fax:_____ Email (required):_____

This continuing education activity is provided by

CME Outfitters

JC-003-100608-13